Monograph Details
|
|
Respiratory Tract
> Rhinitis/rhinorrhea (intranasal products)
|
|
NASALIDE |
| Manufacturer |
|
Teva Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Steroid. |
| Generic Name |
|
Flunisolide 25micrograms/spray; nasal soln. |
| Indications |
|
Refractory allergic rhinitis. |
| Children |
|
<6yrs: not recommended. 6–14yrs: Initially 1 spray in each nostril 3 times daily or 2 sprays twice daily; max 4 sprays/nostril per day. |
| Adults |
|
≥15yrs: Initially 2 sprays in each nostril twice daily; max 8 sprays/nostril per day. |
| Contraindications |
|
Untreated nasal infections. |
| Precautions |
|
Maintain regular regimen. Respiratory tract tuberculosis. Infections (eg, ocular herpes simplex). If exposed to measles or chickenpox, consider anti-infective prophylactic therapy. Reduce dose as condition improves. May use nasal decongestants if needed. Discontinue if no effect after 3 wks. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with topical corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, depression). Monitor for growth suppression in children. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually), and candida infection or other nasal mucosal changes. Avoid eyes. Pregnancy (Cat.C). Nursing mothers. |
| Adverse Reactions |
|
Nasal discomfort, congestion, sneezing, epistaxis, lacrimation, sore throat, nausea, headache, loss of taste and smell, septal perforation, hypercorticism, fungal overgrowth, impaired wound healing, glaucoma, reduced growth velocity in children. |
| How Supplied |
|
Spray—25mL (200 sprays) |
|
|
|
|
